Effects of Neurodynamics on Lower Extremity Spasticity - a Study in Chronic Stroke

Sponsor
National Yang Ming University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05183100
Collaborator
(none)
20
1
2
4.4
4.6

Study Details

Study Description

Brief Summary

Post-stroke spasticity in the lower extremity affects balance and gait, leading to decreased mobility and functional independence. Therefore, effective intervention for reducing spasticity is crucial in stroke rehabilitation. Recently, neurodynamics, though originally designed for pain management in orthopedic patients, has also been applied for treating spasticity in patients with neurological disorders. However, previous studies focused mainly on treating the upper extremity spasticity, but not on lower extremity spasticity, and not on possible neurophysiological changes. The present study aims to investigate the immediate effects of neurodynamics in reducing lower limb spasticity and neurophysiological changes in people with chronic stroke.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Tibial Nerve Neurodynamics
  • Procedure: Lying in supine
N/A

Detailed Description

Sample size calculation: There was no reference for the effect size of neurodymanics on reducing lower extremity spasticity, and the effect size of neurodynamics treatment for improving knee range of motion was between 0.89 to 2.55. We set the effect size of 0.6 (moderate effect size) with an alpha level of 5%, power at 80%, and a paired t-test model to calculate the sample size.

Statistical analysis: Paired t-test will be used for within condition (experimental or control condition) comparisons. The change values between pre and post in each condition will be calculated and compared by paired t-test for between condition comparisons. The significance is set at p< 0.05.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Neurodynamics on Lower Extremity Spasticity - a Study in Chronic Stroke
Actual Study Start Date :
Oct 18, 2021
Anticipated Primary Completion Date :
Feb 28, 2022
Anticipated Study Completion Date :
Feb 28, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Condition (Neurodynamics Treatment)

Neurodynamic treatment for about 13 minutes in supine position. It will be comprised of three stages, and the tensioner technique of the tibial nerve will be used.

Procedure: Tibial Nerve Neurodynamics
The patient will lie supine with the trunk and neck in neutral position. During the first stage, participants will receive passive straight leg raise of the affected side held for 20 seconds for 3 repetitions. In the second stage, hip adduction and internal rotation, ankle dorsiflexion, and ankle eversion are added in the straight leg raise position. Slow oscillations of the ankle movement for 1 minute will be applied, followed by holding the position for 20 seconds, for 3 repetitions. In the third stage, the head of the patient will be held in flexion with pillows while the same oscillation procedure as the second stage is performed. There will be a 2-minute rest between the stages.
Other Names:
  • Tibial Nerve Neural Mobilization
  • Active Comparator: Control Condition

    Lying in supine.

    Procedure: Lying in supine
    Lying in supine position for about 13 minutes.

    Outcome Measures

    Primary Outcome Measures

    1. Change in Spasticity: Clinical measurement [Before intervention and immediately after intervention]

      The modified Ashworth scale (MAS) will be used, which is a 6-point scale commonly used to assess muscle spasticity in clinical settings.

    2. Change in Spasticity: Neurophysiological measurement [Before intervention and immediately after intervention]

      The H-reflex will be recorded by placing a disposable surface electrode on the muscle belly of the gastrocnemius after a stimulation of the tibial nerve just proximal to the electrode.

    Secondary Outcome Measures

    1. Change in Gait Performance [Before intervention and immediately after intervention]

      Gait performance will be measured by using the GAITRite system (CIR system, Inc., Havertown, Pennsylvania). Participants will be instructed to walk along the walkway at their comfortable speed. Gait velocity, cadence, and step length of the affected and unaffected limbs, and spatial and temporal asymmetry ratios are calculated.

    2. Change in Lower Extremity Motor Control [Before intervention and immediately after intervention]

      Motor control of the lower extremity will be assessed by the motor section of the Fugl-Meyer Assessment (FMA). Higher scores represent better motor control, with a total score of 34.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • diagnosis of first-ever stroke with unilateral lesion for more than 6 months

    • demonstrating calf muscle spasticity as indicated by modified Ashworth scale equal to or greater than 1

    • with passive ROM of ankle dorsiflexion at least to neutral position (defined as 0°)

    • ability to walk at least 10m independently without a walking device or ankle-foot orthosis (AFO)

    • sufficient cognition (mini-mental state examination, MMSE score of 24 or higher)

    Exclusion Criteria:
    • contraindications to nerve conduction tests

    • other orthopedic and neurological disorders interfering participating in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Yang Ming Chiao Tung University Taipei Taiwan 112304

    Sponsors and Collaborators

    • National Yang Ming University

    Investigators

    • Principal Investigator: Ray-Yau Wang, National Yang Ming Chiao Tung University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    National Yang Ming University
    ClinicalTrials.gov Identifier:
    NCT05183100
    Other Study ID Numbers:
    • YM110045E
    First Posted:
    Jan 10, 2022
    Last Update Posted:
    Jan 10, 2022
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Yang Ming University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 10, 2022